H.C. Wainwright cuts Oculis stock price target on failed trial By Investing.com

Oculis' Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 failed both the primary endpoint and key secondary endpoint in diabetic macular edema, prompting the company to abandon plans for an FDA filing in that indication. H.C. Wainwright cut its price target to $26 from $47, although it kept a Buy rating and maintained OCS-01's post-ocular-surgery inflammation and pain indication. The stock is down 23% over the past week to $22.70, reflecting the negative readout, while the company retains a strong balance sheet with more cash than debt and a current ratio of 5.96.

Analysis

The market is likely underestimating how much of OCS’s valuation was implicitly tied to a one-asset, one-indication “binary upside” story. With the retinal DME program now effectively off the table, the investable thesis shifts from platform optionality to a narrower cash-runway narrative, which usually drives a second leg lower after the initial trial shock once models reset and specialist holders de-risk. The key distinction is that the company is not facing an existential liquidity event today, but it is facing a duration problem: without a near-term clinical catalyst of similar scale, the market typically assigns biotech cash plus little value to the remaining pipeline until proof points emerge.

The more interesting second-order effect is competitive, not company-specific. A failed non-invasive DME approach reduces pressure on injectable retina incumbents and may allow existing anti-VEGF and steroid players to defend procedure-based economics longer than the market expected. That matters because the original bull case for topical therapy was not just efficacy, but convenience-driven share capture; when that pathway gets delayed, payers and retina specialists have less incentive to accelerate adoption of an unproven alternative class.

The contrarian angle is that the selloff may already reflect the permanent damage to the DME program, but not yet the value of the surviving assets. If the post-surgical inflammation/pain indication can be re-rated as the lead asset, the stock could stabilize once investors stop marking it as a “failed phase 3 biotech” and start treating it as a smaller, cleaner single-asset story. Near-term catalysts are likely to be headlines around analyst model cuts, capital allocation, and any cash burn commentary over the next 1-2 quarters; absent a new clinical readout, multiple compression is the higher-probability path.

Key Decisions for Investors

• Avoid bottom-fishing the common equity for the next 4-8 weeks; let post-cut estimate resets and holder capitulation run before considering any long entry.
• If trading the downside, use put spreads rather than outright shorts: buy 1-3 month OCS puts financed with a lower strike to express another 10-20% downside while limiting borrow and binary rebound risk.
• Pair trade idea: short OCS vs long a profitable retina/inflammation peer or basket, as OCS now carries higher catalyst risk and lower fundamental support while peers retain clearer commercialization visibility.
• For investors already long, trim into any relief rallies over the next 1-2 trading sessions; the most likely path is a slower grind lower as models are reworked, not an immediate V-shaped recovery.
• Watch for a credible new lead-asset narrative or partnership within 1-2 quarters; only then does the stock merit a re-entry, with the risk/reward improving meaningfully if the market stops valuing it solely on failed DME optionality.